Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) has a poor prognosis with low chemotherapeutic efficiency to medications except to sorafenib. Previous studies showed that adverse events (AEs) of sorafenib can predict therapy efficacy to HCC. The aim of the study is to evaluate the early efficacy and AEs...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Shou-Wu, Lee, Teng-Yu, Yang, Sheng-Shun, Tong, Chun-Fang, Yeh, Hong-Zen, Chang, Chi-Sen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396795/
https://www.ncbi.nlm.nih.gov/pubmed/30834030
http://dx.doi.org/10.14740/gr1109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396795/
https://www.ncbi.nlm.nih.gov/pubmed/30834030
http://dx.doi.org/10.14740/gr1109

Ejemplares similares